TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29973256

Group type: EXPERIMENTAL
Intervention: Topical application of 25% silver nitrate (AgNO3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) varnish with functionalized tricalcium phosphate (fTCP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study: 29973911

Group type: EXPERIMENTAL
Intervention: Firearm use
Number of subjects: 0

Group type: COMPARATOR
Intervention: No firearm use
Number of subjects: 0
Study: 29974390

Group type: EXPERIMENTAL
Intervention: Fallers with upper-limb fracture
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fallers without fracture
Number of subjects: 80
Study: 29974618

Group type: EXPERIMENTAL
Intervention: iGlarLixi (simultaneous administration of insulin glargine 100 U and lixisenatide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential iGlar + Lixi (sequential administration of insulin glargine and lixisenatide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0
Study: 29975012

Group type: EXPERIMENTAL
Intervention: Patients without widespread pain (WP) receiving biologic or conventional synthetic disease-modifying antirheumatic drugs (DMARDs)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Patients with baseline color Doppler activity (n = 42 [61%]) receiving biologic or conventional synthetic DMARDs
Number of subjects: 69

Group type: COMPARATOR
Intervention: Patients with widespread nonarthritic pain (WP) receiving biologic or conventional synthetic DMARDs
Number of subjects: 69
Study: 29976121

Group type: EXPERIMENTAL
Intervention: Modified Mini-Mental State (3MS) examination
Number of subjects: 19300

Group type: EXPERIMENTAL
Intervention: Factor analysis of 3MS scores
Number of subjects: 19300
Study: 29976172

Group type: EXPERIMENTAL
Intervention: High performance functional assay for individual radiosensitivity (IRS)
Number of subjects: 222
Study: 29976218

Group type: EXPERIMENTAL
Intervention: valanafusp alpha (1, 3, or 6 mg/kg) administered via weekly intravenous infusion for 52 weeks
Number of subjects: 11
Study: 29976227

Group type: COMPARATOR
Intervention: Traditional occlusive dressing
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Aquacel Surgical
Number of subjects: 550
Study: 29976287

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 11121
Study: 29976297

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29976503

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation therapy (CCRT)
Number of subjects: 37
Study: 29976650

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 426
Study: 29977205

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention to enhance medication adherence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 29977284

Group type: EXPERIMENTAL
Intervention: Combination of serum TFF3 and pepsinogen
Number of subjects: 281

Group type: COMPARATOR
Intervention: TFF3 alone
Number of subjects: 281

Group type: COMPARATOR
Intervention: Pepsinogen test alone
Number of subjects: 281
Study: 29977593

Group type: EXPERIMENTAL
Intervention: HENRY programme (8-week programme delivered to parents)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care (usual provision of services within children's centres)
Number of subjects: 120
Study: 29977603

Group type: EXPERIMENTAL
Intervention: Antimicrobial phototherapy using GLO™ Science device, emitting light at 475 nm and 3 W, applied in 2 cycles of 8 min
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Antimicrobial phototherapy
Number of subjects: 31
Study: 29978216

Group type: EXPERIMENTAL
Intervention: BIND-014 (60 mg/m2 intravenously on day 1 of 21-day cycles in combination with prednisone)
Number of subjects: 42
Study: 29978298

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided left lateral TAP block combined with RS block (15 ml of 0.5% ropivacaine for TAP and 10 ml of 0.5% ropivacaine for RS)
Number of subjects: 30
Study: 29978342

Group type: EXPERIMENTAL
Intervention: Autologous platelet lysate applied as eye drops four times a day
Number of subjects: 10
Study: 29979092

Group type: EXPERIMENTAL
Intervention: Objective evidence of myocardial ischemia in T2MI patients
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Subjective criteria for diagnosing T2MI
Number of subjects: 1640
Study: 29979355

Group type: EXPERIMENTAL
Intervention: Urgency FI
Number of subjects: 46

Group type: COMPARATOR
Intervention: Passive FI
Number of subjects: 46
Study: 29979745

Group type: EXPERIMENTAL
Intervention: Specialized Rehabilitation Centers (SRC)
Number of subjects: 782

Group type: COMPARATOR
Intervention: Residential Facilities (RF)
Number of subjects: 782
Study: 29980220

Group type: EXPERIMENTAL
Intervention: Cold snaring polypectomy
Number of subjects: 4258

Group type: COMPARATOR
Intervention: Hot snaring polypectomy
Number of subjects: 4258
Study: 29980242

Group type: EXPERIMENTAL
Intervention: Daily second-hand tobacco smoke (SHS) exposure
Number of subjects: 8850

Group type: COMPARATOR
Intervention: Occasional second-hand tobacco smoke (SHS) exposure
Number of subjects: 8850

Group type: COMPARATOR
Intervention: Infrequent second-hand tobacco smoke (SHS) exposure among men
Number of subjects: 8850

Group type: EXPERIMENTAL
Intervention: Daily second-hand tobacco smoke (SHS) exposure among women
Number of subjects: 8850

Group type: EXPERIMENTAL
Intervention: Daily second-hand tobacco smoke (SHS) exposure among men
Number of subjects: 8850
Study: 29980490

Group type: EXPERIMENTAL
Intervention: FOLFIRI + Aflibercept (4 mg/kg body weight delivered intravenously every 2 weeks for a maximum of 12 cycles, followed by aflibercept maintenance)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: FOLFIRI + Aflibercept
Number of subjects: 73
Study: 29980523

Group type: EXPERIMENTAL
Intervention: Quantitative flow ratio (QFR)
Number of subjects: 329

Group type: COMPARATOR
Intervention: 2-dimensional quantitative coronary angiography (2D-QCA)
Number of subjects: 329
Study: 29980524

Group type: EXPERIMENTAL
Intervention: Catheter-related thrombosis
Number of subjects: 3032

Group type: EXPERIMENTAL
Intervention: Venous thromboembolism other than catheter-related
Number of subjects: 3032

Group type: EXPERIMENTAL
Intervention: Risk factors for catheter-related thrombosis
Number of subjects: 3032

Group type: EXPERIMENTAL
Intervention: Risk factors for venous thromboembolism other than catheter-related
Number of subjects: 3032
Study: 29980535

Group type: EXPERIMENTAL
Intervention: 50 mg β3-AR agonist mirabegron
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg β3-AR agonist mirabegron
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29980537

Group type: EXPERIMENTAL
Intervention: HDC/IL2 (histamine dihydrochloride and low-dose interleukin-2)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control cohort (not receiving HDC/IL2)
Number of subjects: 81
Study: 29980542

Group type: EXPERIMENTAL
Intervention: Selective CT fluoroscopy transforaminal epidural steroid (arm 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective CT fluoroscopy transforaminal epidural saline (arm 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15 days tapering dose of oral steroids (arm 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham epidural and oral placebo control (arm 4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All arms (1-4)
Number of subjects: 0
Study: 29980544

Group type: EXPERIMENTAL
Intervention: Improving Care for Cardiovascular Disease in China-AF programme
Number of subjects: 28801
Study: 29980548

Group type: EXPERIMENTAL
Intervention: Psychiatric assessments (Mini International Neuropsychiatric Interview, Kiddie Schedule for Affective Disorders and Schizophrenia -Present and Lifetime Version, Positive and Negative Syndrome Scale, Scale for the Assessment of Negative Symptoms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurocognitive evaluations (IQ, Trail Making Test A/B, verbal fluency)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic analysis using next-generation sequencing on trio (mother, father, and child)
Number of subjects: 0
Study: 29980572

Group type: EXPERIMENTAL
Intervention: Telomere length (TL) in peripheral blood (PB) cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCR-ABL
Number of subjects: 0
Study: 29980655

Group type: EXPERIMENTAL
Intervention: Day 1 to Day 7
Number of subjects: 63

Group type: COMPARATOR
Intervention: Day 1
Number of subjects: 63
Study: 29980656

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29980878

Group type: EXPERIMENTAL
Intervention: Monitoring by a nephrologist at day 90 and every year for 3 years after AKI recovery.
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Albuminuria and eGFR monitoring.
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Development of a prediction score for CKD.
Number of subjects: 1200
Study: 29980894

Group type: EXPERIMENTAL
Intervention: AMG 900 at 40 mg/day with G-CSF
Number of subjects: 29

Group type: COMPARATOR
Intervention: AMG 900
Number of subjects: 29
Study: 29980907

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and axillary dissection
Number of subjects: 488
Study: 29980976

Group type: EXPERIMENTAL
Intervention: Post-ERCP indomethacin
Number of subjects: 790
Study: 29981024

Group type: EXPERIMENTAL
Intervention: Extracellular vesicle (EV) RNA sequencing
Number of subjects: 42
Study: 29981205

Group type: EXPERIMENTAL
Intervention: SRP + 1% MtF gel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SRP + AV gel
Number of subjects: 90

Group type: COMPARATOR
Intervention: SRP + placebo gel
Number of subjects: 90
Study: 29981298

Group type: EXPERIMENTAL
Intervention: Golimumab treatment
Number of subjects: 103
Study: 29981314

Group type: EXPERIMENTAL
Intervention: STand Up Frequently From Stroke (STUFFS) intervention
Number of subjects: 34
Study: 29981568

Group type: EXPERIMENTAL
Intervention: Diabetes shared medical appointments (SMAs)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Peer-to-Peer (P2P) support program
Number of subjects: 28
Study: 29981575

Group type: EXPERIMENTAL
Intervention: Laparoscopic intersphincteric resection (Lap ISR) with intraoperative radiotherapy using low-energy X-rays (Intrabeam XRS)
Number of subjects: 1
Study: 29981580

Group type: EXPERIMENTAL
Intervention: CBD-enriched Cannabis herbal extract
Number of subjects: 28
Study: 29981848

Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP)
Number of subjects: 77
Study: 29982198

Group type: EXPERIMENTAL
Intervention: Increased strength of fetal movements
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Decreased frequency of fetal movements (without increase in strength)
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Daily perception of fetal hiccups
Number of subjects: 1024
Study: 29982213

Group type: EXPERIMENTAL
Intervention: Sipjeondaebo-tang (3g three times a day for 56 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (3g three times a day for 56 days)
Number of subjects: 48
Study: 29982215

Group type: EXPERIMENTAL
Intervention: Perioperative acute covert stroke
Number of subjects: 0

Group type: COMPARATOR
Intervention: Montreal Cognitive Assessment (MoCA) before surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brain MRI study between postoperative days 2 and 9
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA) one year after surgery
Number of subjects: 0
Study: 29982217

Group type: EXPERIMENTAL
Intervention: Oral propranolol-hydrochloride (1.6 mg/kg/day in three to four divided dosages) until discharge, for a maximum of 10 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo until discharge, for a maximum of 10 weeks.
Number of subjects: 0
Study: 29982218

Group type: EXPERIMENTAL
Intervention: Azithromycin (single oral dose at months 6, 9, 12, and 15)
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (3-day course at months 12 and 15)
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: Nicotinamide (daily oral dose given to mother for breastfeeding children aged 0-6 months and directly to children aged 6-18 months)
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: Hydrogen breath assessment
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: Assessment of cognitive development
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: Breastmilk content of nicotinamide, other vitamins and amino acids
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: Blood measures of tryptophan-kynurenine-niacin pathway
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: Stool pathogens
Number of subjects: 1188
Study: 29982223

Group type: EXPERIMENTAL
Intervention: T-SPOT.TB
Number of subjects: 10740

Group type: EXPERIMENTAL
Intervention: Tuberculin skin test
Number of subjects: 10740

Group type: EXPERIMENTAL
Intervention: QuantiFERON
Number of subjects: 10740

Group type: EXPERIMENTAL
Intervention: Latent TB infection prevalence
Number of subjects: 10740
Study: 29982267

Group type: EXPERIMENTAL
Intervention: Households with a member with previously diagnosed hypertension
Number of subjects: 29074

Group type: COMPARATOR
Intervention: Overall population sodium intake
Number of subjects: 29074
Study: 29982279

Group type: EXPERIMENTAL
Intervention: Neoadjuvant anti-PD-1 (nivolumab)
Number of subjects: 20
Study: 29982344

Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) of obesity
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Disinhibition
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Susceptibility to hunger
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Habitual susceptibility to disinhibition
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Situational susceptibility to disinhibition
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Internal locus of hunger
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: External locus of hunger
Number of subjects: 768
Study: 29982449

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusions using flucloxacillin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusions using cefepime
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusions using vancomycin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusions using piperacillin/tazobactam
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusions
Number of subjects: 150
Study: 29982514

Group type: EXPERIMENTAL
Intervention: Pivmecillinam 200 mg three times daily for ≤5 days
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Pivmecillinam 400 mg three times daily
Number of subjects: 162
Study: 29982518

Group type: EXPERIMENTAL
Intervention: HIV group (N = 922)
Number of subjects: 2459

Group type: EXPERIMENTAL
Intervention: CHB group (N = 777)
Number of subjects: 2459

Group type: COMPARATOR
Intervention: Reference group (N = 760)
Number of subjects: 2459
Study: 29982620

Group type: EXPERIMENTAL
Intervention: Dietary intake during basic combat training
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Vitamin D intake
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Linoleic and α-linolenic acid, fiber, vitamin E, magnesium, potassium intake (males)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: α-linolenic acid, fiber, vitamin E, calcium, iron, magnesium, potassium intake (females)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Fat and sodium intake
Number of subjects: 587
Study: 29982724

Group type: EXPERIMENTAL
Intervention: AHEI-2010
Number of subjects: 57078

Group type: EXPERIMENTAL
Intervention: aMED
Number of subjects: 57078

Group type: EXPERIMENTAL
Intervention: DASH
Number of subjects: 57078

Group type: EXPERIMENTAL
Intervention: HDI
Number of subjects: 57078
Study: 29982738

Group type: EXPERIMENTAL
Intervention: Physical training interventions, specific details not available
Number of subjects: 0
Study: 29983087

Group type: EXPERIMENTAL
Intervention: Veliparib (PARP inhibitor)
Number of subjects: 34
Study: 29983355

Group type: EXPERIMENTAL
Intervention: Ivacaftor treatment for 3 months
Number of subjects: 22
Study: 29983597

Group type: EXPERIMENTAL
Intervention: RIG-C (20 IU/kg IM)
Number of subjects: 12
Study: 29983992

Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (CRT) + Teach the Parent
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (CRT) + contact control (Family Fun Time)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 60
Study: 29983993

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Coping Skills group intervention for HCV (CBCS-HCV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 29984044

Group type: EXPERIMENTAL
Intervention: Ozone therapy as an adjunct to sterile saline
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sterile saline alone
Number of subjects: 41
Study: 29984062

Group type: EXPERIMENTAL
Intervention: PREP-GC (Postoperative Recovery Exercise Program)
Number of subjects: 24
Study: 29984589

Group type: EXPERIMENTAL
Intervention: Traditional literacy and education
Number of subjects: 0
Study: 29984608

Group type: EXPERIMENTAL
Intervention: Overused drug withdrawal with optional preventive medication
Number of subjects: 475
Study: 29985674

Group type: EXPERIMENTAL
Intervention: Endovascular embolization of tributaries of the internal iliac veins
Number of subjects: 0
Study: 29985747

Group type: EXPERIMENTAL
Intervention: t-SCNC detection
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: small-cell-like cluster
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: t-SCNC transcriptional signature
Number of subjects: 202
Study: 29985987

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 961
Study: 29986029

Group type: EXPERIMENTAL
Intervention: Drinking 1 cup of coffee per day
Number of subjects: 63257

Group type: EXPERIMENTAL
Intervention: Drinking ≥2 cups of coffee per day
Number of subjects: 63257

Group type: EXPERIMENTAL
Intervention: Drinking ≥2 cups of coffee per day (men)
Number of subjects: 63257

Group type: EXPERIMENTAL
Intervention: Drinking ≥2 cups of coffee per day (women)
Number of subjects: 63257

Group type: COMPARATOR
Intervention: Tea, soda, or total caffeine consumption
Number of subjects: 63257
Study: 29986085

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (Xyrem) oral solution, median dose 4.5 g per night at start, 6 g per night throughout study, in two equal doses.
Number of subjects: 670
Study: 29986669

Group type: EXPERIMENTAL
Intervention: Patient QoL-AD evaluation
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Caregiver evaluations
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Overall evaluation
Number of subjects: 123
Study: 29986672

Group type: EXPERIMENTAL
Intervention: SMS reminder (weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (no SMS reminder)
Number of subjects: 0
Study: 29986691

Group type: EXPERIMENTAL
Intervention: Bendamustine 75 mg/m²
Number of subjects: 10
Study: 29986710

Group type: EXPERIMENTAL
Intervention: Major TBI group (AIS head > 2)
Number of subjects: 199

Group type: COMPARATOR
Intervention: No or mild TBI group (AIS head ≤ 2)
Number of subjects: 199
Study: 29986786

Group type: EXPERIMENTAL
Intervention: e-cigarette intervention (6-week free e-cigarettes)
Number of subjects: 50
Study: 29986845

Group type: EXPERIMENTAL
Intervention: WelTel short-message service (SMS) mHealth program; participants received mobile phones with unlimited texting and weekly bidirectional text messages for one year
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: WelTel short-message service (SMS) mHealth program
Number of subjects: 85
Study: 29986852

Group type: EXPERIMENTAL
Intervention: Lenalidomide at 10-, 15-, and 20-mg dose levels
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance after salvage with high-dose methotrexate or focal irradiation
Number of subjects: 14
Study: 29987139

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination tablet of dolutegravir (50 mg) and rilpivirine (25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Separate tablets of dolutegravir and rilpivirine (reference treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination tablet
Number of subjects: 0
Study: 29987142

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (10 to 15 mg/kg body weight every 12 h)
Number of subjects: 0
Study: 29987605

Group type: EXPERIMENTAL
Intervention: Breast-Conserving Therapy (BCT)
Number of subjects: 198
Study: 29987806

Group type: EXPERIMENTAL
Intervention: Deceased organ donor management
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Data collection on organ recipients
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Completion of case report forms (CRFs)
Number of subjects: 67
Study: 29988004

Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Test (RDT) based on antigen detection (CL Detect Rapid Test)
Number of subjects: 0
Study: 29988503

Group type: EXPERIMENTAL
Intervention: Preventive Dexamethasone Treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 29988514

Group type: EXPERIMENTAL
Intervention: rasagiline 1 mg/day
Number of subjects: 324

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 324
Study: 29988751

Group type: EXPERIMENTAL
Intervention: Tailored telephone and email-based exercise intervention
Number of subjects: 111

Group type: COMPARATOR
Intervention: No-information control group
Number of subjects: 111
Study: 29988921

Group type: EXPERIMENTAL
Intervention: Bortezomib (4 doses of 1.3 mg/m2 i.v.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 8
Study: 29989087

Group type: EXPERIMENTAL
Intervention: Family Integrated Care (FICare)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29989515

Group type: EXPERIMENTAL
Intervention: Superior hypogastric nerve block (SHNB)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 44
Study: 29989854

Group type: EXPERIMENTAL
Intervention: Ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression
Number of subjects: 18
Study: 29989911

Group type: EXPERIMENTAL
Intervention: Age/Sex/Gene Expression Score (ASGES) - low (<=15)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Age/Sex/Gene Expression Score (ASGES) - elevated (>15)
Number of subjects: 566
Study: 29991024

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg once daily
Number of subjects: 106
Study: 29991428

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) for 8 weeks (n = 29)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Waitlist control condition (n = 16)
Number of subjects: 45